Physician profile
Paul Defranco
NPI 1952453839
$385.96
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $297 · 2020: $66.49 · 2022: $22.42.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $58.11 | 2019-2020 | |
| Abbvie INC. | $57.81 | 2019 | |
| Smith+Nephew, INC. | $43.48 | 2020-2022 | |
| Novo Nordisk INC | $32.48 | 2019-2020 | |
| Amarin Pharma, INC. | $28.31 | 2019-2020 | |
| Scilex Pharmaceuticals INC. | $28.00 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $27.77 | 2019 | |
| Radius Health, INC. | $26.62 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.46 | 2019 | |
| Collegium Pharmaceutical, INC. | $14.38 | 2019 | |
| Daiichi Sankyo INC. | $14.36 | 2019 | |
| Sunovion Pharmaceuticals INC. | $14.19 | 2019 | |
| Novartis Pharmaceuticals Corporation | $14.00 | 2019 | |
| Amgen INC. | $11.99 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Defranco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.